video

sound

Persian Version

View:

856

Download:

337

Cites:

Information Journal Paper

Title

Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital

Pages

  75-81

Abstract

 Background: We investigated therapeutic outcomes of Radium-223 (Ra-223) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Materials and Methods: Outcomes were retrospectively examined in 20 patients starting Ra-223 treatment at a single university hospital from January 2017 to January 2020. Results: Median patient age was 70 years. Median values included prostate specific antigen (PSA) 10. 73 ng/ml, PSA doubling time (PSADT) 3. 7 months, alkaline phosphatase (ALP) 315 IU/L, lactate dehydrogenase (LDH) 186 IU/L, neutrophil-to-lymphocyte ratio (NLR) 2. 22, and Gleason score 9. Extent of disease (EOD) was 3 or more in 55%, and Eastern Cooperative Oncology Group performance status was 0 in 80%. 16 patients (80%) completed Ra-223 treatment. Ra-223 was administered in 11 (55%) with ≤,3 lines of treatment and 9 (45%) with ≥,4. Concomitant drug was enzalutamide and abiraterone in 6 and 7 patients, respectively. Bone modifier agents (BMA) were used in 11 patients. Symptomatic skeletal events (SSE. occurred in 5 patients and were associated with abiraterone combination. BMA during Ra-223 treatment did not affect SSE. Median overall survival from initiation of Ra-223 treatment was 32. 7 months. Prognosis was significantly better with PSADT ≤,3 months, EOD ≤,2, no SSE. no opioid use, and completion of Ra-223 treatment. PSA, LDH, NLR, PSADT, and Ra-223 treatment line after mCRPC were associated with Ra-223 completion. Anemia of Grade 3 occurred in 1 patient. Conclusion: Ra-223 treatment is safe, with good prognosis if completed. Combination treatment with abiraterone during Ra-223 treatment may cause SSE.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    TAKAYAMA, T., Sugihara, T., KAMEDA, T., YAMAZAKI, M., Komatsubara, M., KAMEI, J., Fujisaki, A., ANDO, S., & FUJIMURA, T.. (2022). Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital. INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 20(1), 75-81. SID. https://sid.ir/paper/989502/en

    Vancouver: Copy

    TAKAYAMA T., Sugihara T., KAMEDA T., YAMAZAKI M., Komatsubara M., KAMEI J., Fujisaki A., ANDO S., FUJIMURA T.. Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital. INTERNATIONAL JOURNAL OF RADIATION RESEARCH[Internet]. 2022;20(1):75-81. Available from: https://sid.ir/paper/989502/en

    IEEE: Copy

    T. TAKAYAMA, T. Sugihara, T. KAMEDA, M. YAMAZAKI, M. Komatsubara, J. KAMEI, A. Fujisaki, S. ANDO, and T. FUJIMURA, “Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital,” INTERNATIONAL JOURNAL OF RADIATION RESEARCH, vol. 20, no. 1, pp. 75–81, 2022, [Online]. Available: https://sid.ir/paper/989502/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops